HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)
HDAC抑制剂tucidinostat和节拍式卡培他滨联合内分泌治疗用于CDK4/6抑制剂治疗后HR阳性HER2阴性晚期乳腺癌患者：一项多中心2期研究的临床结果和探索性循环肿瘤细胞和ctDNA生物标志物分析（SYSUCC-020试验）
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-026-02632-5
Wu, Huai-Liang; Xia, Wen; Xu, Zhengyang; Zhou, Hanxing; Chen, Limin; Lu, Yongkui; Liu, Xinlan; Pang, Danmei; Liu, Yan; Lu, Qianyi; Xu, Fei; An, Xin; Huang, Jiajia; Jiang, Kuikui; Zhang, Jingmin; Cai, Yili; Hong, Ruoxi; Zheng, Qiufan; Wang, Shusen
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
细胞生物学
肿瘤细胞
